US Patent

US11147817 — Pharmaceutical composition of pemetrexed

Formulation · Assigned to FTF Pharma Pvt Ltd · Expires 2035-03-26 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition of pemetrexed, specifically a ready-to-use injection with certain quality control standards.

USPTO Abstract

The present invention relates to pharmaceutical composition comprising pemetrexed, a ready to use injection comprising pemetrexed. Liquid composition of pemetrexed comprises head space oxygen less than 5%, dissolved oxygen less than 2 ppm and individual impurity level less than 0.2%.

Drugs covered by this patent

pemetrexed-disodium (PEMETREXED DISODIUM)

Patent Metadata

Patent number: US11147817
Jurisdiction: US
Classification: Formulation
Expires: 2035-03-26
Drug substance claim: No
Drug product claim: Yes
Assignee: FTF Pharma Pvt Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.